Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: Results from three Phase 3, multicentre, double-blind, randomised trials
Lancet 2022;399(10341):2113–28 doi: 10.1016/S0140-6736(22)00581-5
The results of two induction studies (UC1 and UC2) and a maintenance study (UC3) show upadacitinib superiority to placebo in treating ulcerative colitis (UC). Rates of clinical remission were significantly higher for all upadacitinib doses versus placebo in all three studies.
Three Phase 3, multicentre, randomised, double-blind, placebo-controlled trials were conducted. UC1 and UC2 were replicate induction studies in which patients with UC were randomised 1:1 to upadacitinib or placebo and observed for up to 16 weeks. UC3 [JM1] included patients treated with upadacitinib 15 mg, upadacitinib 30 mg, or placebo for 52 weeks.
